# Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC

> **NCT02650271** · PHASE3 · COMPLETED · sponsor: **Guangxi Medical University** · enrollment: 240 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Entecavir
- **DRUG:** Tenofovir

## Key facts

- **NCT ID:** NCT02650271
- **Lead sponsor:** Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-02
- **Primary completion:** 2023-12-25
- **Final completion:** 2023-12-30
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2024-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02650271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02650271, "Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02650271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*